SVA
Sinovac Biotech LtdNASDAQ
Healthcare • Biotechnology
Updated 9 days ago
Coverage limited
$6.470.00%
Close Jul 7, 2026
- Market cap
- $464.94M
- 1 month
- —
- 3 months
- —
- 1 year
- —
- Dividend
- No payments on record
- Short interest
- 0.1% of float82.2K shares · settled Sep 30, 2026 · 0.0% since Sep 15, 2026 · FINRA
End-of-day close from stored market data, not a live quote.
Portfolio context
Sign in to see your position size
We’ll show you if SVA is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
Smart money context
Holder IQ: MEDIUM
1 top institutions tracked
as of 2026-Q2 (filed 2026-08-17)
Insider context
Sentiment: unknown
No recent insider trades detected.
Red flags: 0
Largest 13-F holders · Q2 2026
9 filers reported a long position in SVA for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| ORBIMED ADVISORS LLC | $184.5M | 2.7M | Unchanged |
| Vivo Capital, LLC | $38.2M | 5.9M | Unchanged |
| Neumann Advisory Hong Kong Ltd | $2M | 315.6K | Unchanged |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $106.3K | 16.4K | Unchanged |
| MORGAN STANLEY | $59.2K | 9.1K | 0% |
| WELLS FARGO & COMPANY/MN | $29.6K | 4.6K | -4.8% |
| UBS Group AG | $16K | 2.5K | +11.2% |
| HARBOUR INVESTMENTS, INC. | $503 | 78 | -6% |
| Horizon Investments, LLC | $336 | 52 | -50% |
Get the Full Analysis for SVA
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.